Blueprint Medicines Competitors and Similar CompaniesClear all
Blueprint Medicines's competitors and similar companies include Deciphera Pharmaceuticals, AstraZeneca United States, Halozyme Therapeutics, Ohm Oncology and Repare Therapeutics.
 Blueprint Medicines Blueprint Medicines is a biopharmaceutical company engaged in developing therapies for allergy, inflammation, and oncology/hematology. |  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Ohm Oncology Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds. |  Repare Therapeutics Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells. | ||
Founding Date | Founding Date 2011 | Founding Date 2003 | Founding Date N/A | Founding Date 1998 | Founding Date 2015 | Founding Date 2016 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Private | Type Public |
Tags | ||||||
Locations | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH | Locations Waltham, US HQ Lawrence, US | Locations Wilmington, US HQ Gaithersburg, US | Locations San Diego, US HQ | Locations Austin, US HQ | Locations Montréal, CA HQ Cambridge, US |
Employees | Employees 6552% increase | Employees 35037% increase | Employees N/A | Employees 373157% increase | Employees 167% decrease | Employees 129 |
Valuation ($) | Valuation ($) 5.3 b | Valuation ($) 2.2 b | Valuation ($) N/A | Valuation ($) 6.4 b | Valuation ($) N/A | Valuation ($) 152.4 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $508.8m (FY, 2024) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $53.5m (FY, 2024) |
Cost of goods | Cost of goods $20.2m (FY, 2024) | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $488.7m (FY, 2024) | Gross profit $159.6m (FY, 2023) | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit N/A | Gross profit $53.5m (FY, 2024) |
Net income | Net income ($67.1m) (FY, 2024) | Net income ($194.9m) (FY, 2023) | Net income N/A | Net income $316.9m (FY, 2025) | Net income N/A | Net income ($84.7m) (FY, 2024) |
Operating ⚠ | ||||||
Patent Applications | Patent Applications N/A | Patent Applications 49 (Aug, 2017) | Patent Applications N/A | Patent Applications 50 (FY, 2020) | Patent Applications N/A | Patent Applications N/A |
Patents (US) | Patents (US) N/A | Patents (US) 11 (Aug, 2017) | Patents (US) N/A | Patents (US) 43 (FY, 2020) | Patents (US) N/A | Patents (US) N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 1.7b | Total funding raised $ 714m | Total funding raised N/A | Total funding raised $ 171.9m | Total funding raised N/A | Total funding raised $ 150.5m |
For sources of this data, please see the company profile
View Company Profiles
Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View company
AstraZeneca United States
HQ
Wilmington, US
AstraZeneca United States is a biopharmaceutical company.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyOhm Oncology
HQ
Austin, US
Employees
1
Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds.
View company